car-t vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
Published 8 months ago • 214 plays • Length 4:49Download video MP4
Download video MP3
Similar videos
-
2:06
an insight into the sequencing of car-t and bispecifics in myeloma
-
6:38
comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
1:46
car-t therapy vs bites in multiple myeloma: current outlooks & the importance of patient selection
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
5:30
linvoseltamab versus teclistamab for tce rrmm and the sequencing of bispecifics with car-ts
-
7:14
car-ts in multiple myeloma: their current role and the future
-
6:23
the benefits of bispecific antibodies over car-t cell therapy in lymphoma
-
4:01
what are the differences between car t-cell therapy and bispecific antibodies?
-
6:40
car-t vs bispecifics: the best immune approach to replace asct
-
3:44
clinical advances with car-ts and bispecifics in r/r myeloma
-
0:39
car-t, bispecifics and mrd: how is treatment for multiple myeloma evolving?
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
2:01
car-t updates in myeloma
-
1:31
integrating bcma-directed bispecifics and car-t into the myeloma treatment landscape
-
1:13
the future of car t-cells and bispecific antibodies to treat myeloma
-
1:14
the car t-cell strategy vs bispecific antibodies
-
4:01
determining the optimal sequencing of anti-bcma therapies in multiple myeloma
-
2:16
autosct vs car-t for patients with relapsed lbcl in pr: the role of total metabolic tumor volume
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells